Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...
Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Diagnosis involves blood, urine, and bone marrow tests, with ...
Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.
Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...
Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...
Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.
News Medical on MSN
Novel RNA molecule may influence patient survival in certain blood cancers
In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at the Texas A&M University Health Science Center (Texas A&M Health) identify a novel RNA ...
Gilead Sciences, Inc. shares have risen more than 43% over the past year. Click here to find out why GILD stock is a Sell.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...
The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...
In a recent study, researchers at the Texas A&M University Health Science Center (Texas A&M Health) identify a novel RNA molecule that plays a crucial role in preserving the integrity of a key ...
Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript February 3, 2026 Pfizer Inc. beats earnings expectations. Reported EPS is $0.66, expectations were $0.567. Francesca DeMartino: Good day, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results